Page last updated: 2024-11-05

lutetium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lutetium is a rare-earth metal found in various minerals. Its synthesis involves extraction from these minerals through a complex process. Lutetium isotopes, particularly Lu-177, are used in nuclear medicine for treating cancer. Lutetium is studied for its potential in various applications, such as high-intensity light sources, catalysts, and advanced materials.'

Lutetium: An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23929
CHEBI ID33382
MeSH IDM0012765

Synonyms (51)

Synonym
lutetium
LU ,
7439-94-3
lutecium
lutetium atom
71lu
lutecio
CHEBI:33382
cassiopeium
cassiopium
lutetium trihydride
einecs 231-103-0
5h0doz21uj ,
unii-5h0doz21uj
cassiopeum
lutetium [mi]
lutetium, elemental
AKOS015902696
DTXSID5047746 ,
lutetium foil, 0.5mm (0.02in) thick
lutetium pieces
lutetium foil, 0.1mm (0.004in) thick
lutetium pieces, distilled dendritic
lutetium, dendritic pieces, purified by distillation, 99.99% trace metals basis
mfcd00011098
lutetium powder, 3n
lutetium foil
lutetium ingot, 3n
lutetium, foil, thickness 0.15 mm, size 25 x 25 mm, tolerance 0.2
lutetium, lump, 25 mm max. lump size, weight 1 g, purity 99.9%
lutetium, foil, thickness 0.025 mm, size 25 x 25 mm, purity 99%
lutetium, lump, 25 mm max. lump size, weight 2 g, purity 99.9%
lutetium, foil, thickness 0.025 mm, size 50 x 50 mm, purity 99%
lutetium, foil, thickness 0.1 mm, size 25 x 25 mm, tolerance 0.2
lutetium, powder, 1g, max. particle size 500 micron, 99.9%
lutetium, foil, thickness 0.125 mm, size 25 x 25 mm, tolerance 0.2
lutetium, foil, thickness 1.0 mm, size 25 x 25 mm, purity 99%
lutetium, foil, thickness 0.125 mm, size 50 x 50 mm, tolerance 0.2
lutetium, chips
hydrido lutetium
lutetium nanofoil
Q1857
manganese telluride (mnte) sputtering targets
lutetium (iii) hydride
lutetium dihydride
dtxcid9027730
lutetium internal standard: lu @ 10 microg/ml in 2% hno3
lutetium standard: lu @ 10000 microg/ml in 5% hno3
lutetium standard: lu @ 10 microg/ml in 2% hno3
lutetium standard: lu @ 1000 microg/ml in 5% hno3
lutetium - lu @ 1000 microg/ml in 5% hno3

Research Excerpts

Overview

Lutetium-177 is a rare earth metal in the lanthanides series which decays by beta emission with a half life of 6.647 days to three excited states and the ground state of (177)Hf. It is expected to become one of the most widely used therapeutic radionuclides.

ExcerptReferenceRelevance
"Lutetium-177 is an assured therapeutic radionuclide with favorable half-life and suitable β(-) energy. "( Camptothecin Enhances Cell Death Induced by (177)Lu-EDTMP in Osteosarcoma Cells.
Korde, A; Kumar, C; Lohar, SP; Samuel, G; Vats, K, 2014
)
1.85
"Lutetium-177 ((177)Lu) is a rare earth metal in the lanthanides series which decays by beta emission with a half life of 6.647 days to three excited states and the ground state of (177)Hf. "( Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry.
Konijnenberg, MW, 2015
)
1.86
"Lutetium-177 is a widely used therapeutic radionuclide in targeted therapy and it is important to know its specific activity at the time of radiopharmaceutical preparation, especially for radiolabeling peptides. "( Estimation of specific activity of 177Lu by 'saturation assay' principle using DOTA as ligand.
Chakraborty, S; Das, T; Pillai, AM, 2015
)
1.86
"Lutetium-177 ((177)Lu) is a late entrant into the nuclear medicine therapy arena but is expected to become one of the most widely used therapeutic radionuclides. "( Evolving Important Role of Lutetium-177 for Therapeutic Nuclear Medicine.
Knapp, FF; Pillai, AM, 2015
)
2.16
"Lutetium-177 (177Lu) is a radionuclide of interest for radioimmunoimaging (RII) and radioimmunotherapy (RIT) on account of its short half-life (161 h) and the ability to emit both beta and gamma radiation. "( Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Batra, SK; Chauhan, SC; Colcher, D; Gwilt, PR; Jain, M; Li, J; Moore, ED; Wittel, UA, 2005
)
1.77
"177Lutetium (177Lu) is a member of the family of elements known as lanthanides or rare earths. "( Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.
Cheng, R; Colcher, D; Eggensperger, D; Goeckeler, W; Houchens, D; Kaplan, D; Milenic, DE; Miller, LS; Schlom, J; Siler, K, 1991
)
1.14

Effects

ExcerptReferenceRelevance
"Lutetium-177 (177Lu) has both beta particle emissions for a therapeutic effect and gamma emissions for imaging. "( 177Lu-EDTMP: a potential therapeutic bone agent.
Ando, A; Ando, I; Fujita, N; Kataiwa, A; Kazuma, K; Kinuya, S; Nakagawa, M; Tonami, N, 1998
)
1.74

Toxicity

ExcerptReferenceRelevance
" All ligands were tested separately to ensure that their concentrations would not cause adverse effects themselves."( Lutetium speciation and toxicity in a microbial bioassay: testing the free-ion model for lanthanides.
Hamers, T; Verhoof, LR; Verweij, W; Weltje, L, 2004
)
1.77
" However, treatment with therapeutically effective activities of (177)Lu-d9MAb was not free of toxic side effects."( 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Beck, R; Bruchertseifer, F; Quintanilla-Martinez, L; Seidl, C; Senekowitsch-Schmidtke, R; Zöckler, C, 2011
)
0.37
"The therapeutic efficacy of (177)Lu-d9MAb conjugates in peritoneal carcinomatosis is impaired by toxic side effects."( 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Beck, R; Bruchertseifer, F; Quintanilla-Martinez, L; Seidl, C; Senekowitsch-Schmidtke, R; Zöckler, C, 2011
)
0.37
" All patients tolerated the therapy without any acute adverse effects."( 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum, RP; Klette, I; Kulkarni, HR; Mueller, D; Schottelius, M; Schuchardt, C; Singh, A; Wester, HJ; Wiessalla, S; Wirtz, M, 2016
)
0.43
" These results confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile."( Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Ahmadzadehfar, H; Eppard, E; Essler, M; Fimmers, R; Gärtner, F; Kürpig, S; Rogenhofer, S; Schlenkhoff, CD; Yordanova, A, 2016
)
0.43
" Our findings demonstrate that (177)Lu-PSMA is a safe treatment modality to be applied as an outpatient protocol, since the dose rate decreases below the determined threshold of  <30 μSv h(-1) after approximately 5 h and degrades to 20 μSv h(-1) after 6 h."( Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol.
Abuqbeitah, M; Çavdar, İ; Demir, M; Gündüz, H; Kabasakal, L; Uslu-Beşli, L; Vatankulu, B; Yeyin, N; Yıldırım, Ö, 2016
)
0.43
" Commenced 15 years ago, PRRT is now becoming established as first- and second-line therapy for gastroentero pancreatic neuroendocrine tumors (GEPNETs), and early treatment minimizes myelotoxicity, which is the most significant potential adverse event following PRRT."( Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Kesavan, M; Turner, JH, 2016
)
0.43
" None of the patients experienced a disabling or life-threatening grade 4 adverse event according to the Common Toxicity Criteria (CTC)."( Outcome and safety of rechallenge [
Ahmadzadehfar, H; Essler, M; Feldmann, G; Gaertner, FC; Hauser, S; Kürpig, S; Linden, P; Meisenheimer, M; Yordanova, A, 2019
)
0.51
" Potential toxic effects of LNs were observed only in five species of the seven studied, predominantly in the unicellular organism (A."( Assessment of the toxic effects of mixtures of three lanthanides (Ce, Gd, Lu) to aquatic biota.
Cossu-Leguille, C; Giamberini, L; Joonas, E; Muna, M; Romero-Freire, A; Vignati, DAL, 2019
)
0.51
" Toxicities related to radioligand therapy were low and transient with no serious adverse effects."( Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bal, C; Ballal, S; Damle, NA; Sahoo, RK; Seth, A; Tripathi, M; Yadav, MP, 2020
)
0.56
"Lu-PSMA-617 radionuclide therapy is a safe and effective approach to the treatment of mCRPC patients."( Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bal, C; Ballal, S; Damle, NA; Sahoo, RK; Seth, A; Tripathi, M; Yadav, MP, 2020
)
0.56
"Our results indicate that Lu-PSMA is safe and active in elderly patients with mCRPC."( A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Aharon, M; Ben-Haim, S; Berger, R; Davidson, T; Domachevsky, L; Gadot, M; Leibowitz, R; Levartovsky, M; Malki, A; Oedegaard, C; Saad, A; Sandler, I, 2020
)
0.81
" However, dry mouth is a common side effect that caused about a quarter of patients to stop therapy."( Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Beheshti, A; Bruchertseifer, F; D'Alessandria, C; Eiber, M; Feuerecker, B; Gafita, A; Gschwend, JE; Heck, M; Knorr, K; Kratochwil, C; Morgenstern, A; Pickhard, A; Retz, M; Seidl, C; Tauber, R; Weber, WA, 2021
)
0.83
"To develop predictive models of side effect occurrence in GEPNET treated with PRRT."( Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT.
Argiroffi, G; Baccini, M; Centonze, G; Fuoco, V; Garanzini, EM; Gherardini, L; Kirienko, M; Maccauro, M; Milione, M; Prinzi, N; Pusceddu, S; Scalorbi, F; Seregni, E, 2021
)
0.62
" The vast majority of patients (96/100) was not restricted in treatment continuation by haematotoxicity; therefore, our selection criteria appeared appropriate for safe PRRT treatment."( Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course.
de Vries-Huizing, DMV; de Wit-van der Veen, BJ; Geluk-Jonker, MM; Hendrikx, JJMA; Sinaasappel, M; Stokkel, MPM; Tesselaar, MET; Versleijen, MWJ; Walraven, I, 2021
)
0.62
" No significant adverse events were reported in any of the studies."( [Efficacy and safety of the 177Lu-PSMA-617 therapy in the treatment of metastatic castration-resistant prostate cancer: A meta-analysis].
Xin, P; Zhang, H; Zhang, YX, 2021
)
0.62
"The177Lu-PSMA-617 therapy is a safe and effective option for the treatment of metastatic castration-resistant prostate cancer."( [Efficacy and safety of the 177Lu-PSMA-617 therapy in the treatment of metastatic castration-resistant prostate cancer: A meta-analysis].
Xin, P; Zhang, H; Zhang, YX, 2021
)
0.62
" Xerostomia and myelosuppression are common early treatment-emergent adverse events in patients receiving this therapy; however, data on long-term toxicity are relatively scarce."( Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy.
Gill, HJS; Maheshwari, P; Satapathy, S; Sharma, A; Sood, A, 2022
)
0.72
"This review aims to provide practical advice and clinical considerations for working with [177Lu]Lu-PSMA-617; particularly, regarding the role of nurses in managing radiation safety, monitoring and reporting of adverse events, and counseling patients receiving this therapy."( Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling.
Floyd, R; Gardner, L; Spitz, A; Sutton, J, 2023
)
0.91
"Nurses coordinate safe care for patients receiving [177Lu]Lu-PSMA-617 by facilitating communication among physicians, managing logistic concerns, monitoring for adverse events related to treatment, providing education, and counseling patients and caregivers throughout treatment."( Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling.
Floyd, R; Gardner, L; Spitz, A; Sutton, J, 2023
)
0.91
" Toxicity was assessed using the Common Toxicity Criteria for Adverse Events criteria."( Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer : Oncological Outcomes and Toxicity Profile.
Bavbek, S; Demirkol, MO; Esen, B; Esen, T; Falay, O; Kurtuldu, S; Mandel, NM; Şen, M; Seymen, H; Tilki, D; Uçar, B, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"Lutetium-177 (177Lu) is a radionuclide of interest for radioimmunoimaging (RII) and radioimmunotherapy (RIT) on account of its short half-life (161 h) and the ability to emit both beta and gamma radiation."( Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Batra, SK; Chauhan, SC; Colcher, D; Gwilt, PR; Jain, M; Li, J; Moore, ED; Wittel, UA, 2005
)
1.77
" Based on biexponential decay, the terminal half-life was 44 +/- 15 h for both tracers."( Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Kothari, PA; Kuji, I; Milowski, MI; Nanus, DM; Vallabhajosula, S, 2005
)
0.33
" All the three mAb-BFCA conjugates were labeled with 177Lu(III) and were subsequently evaluated in normal Swiss mice to ascertain their respective pharmacokinetic behavior."( Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Amirdhanayagam, J; Das, T; Dash, A; Guleria, M; Kumar, C; Sarma, HD; Sharma, R, 2018
)
0.48
" 177Lu-labeled mAb-BFCA complex prepared corresponding to 1:10 mAb:BFCA ratio exhibited intermediate pharmacokinetic behaviour with moderate IRF (53."( Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Amirdhanayagam, J; Das, T; Dash, A; Guleria, M; Kumar, C; Sarma, HD; Sharma, R, 2018
)
0.48
"The present study indicates that antibody to BFCA ratio plays a crucial role in determining the immunoreactivity and pharmacokinetic behavior of the radiolabeled antibodies and must be prudently chosen for their successful therapeutic application."( Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Amirdhanayagam, J; Das, T; Dash, A; Guleria, M; Kumar, C; Sarma, HD; Sharma, R, 2018
)
0.48
"The development of (radio)pharmaceuticals with favorable pharmacokinetic profiles is crucial for allowing the optimization of the imaging or therapeutic potential and the minimization of undesired side effects."( Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.
Benešová, M; Borgna, F; Farkas, R; Müller, C; Schibli, R; Schmid, RM, 2017
)
0.46
"In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma."( Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Ahmadzadehfar, H; Bundschuh, RA; Eppard, E; Essler, M; Gaertner, FC; Khawar, A; Kürpig, S; Meisenheimer, M; Roesch, F; Sinnes, JP, 2018
)
0.48
" Total activity measured in source organs by PET imaging, as well as counts per milliliter measured in blood and urine samples, was decay corrected back to the time of injection using the half-life of Sc."( Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Ahmadzadehfar, H; Bundschuh, RA; Eppard, E; Essler, M; Gaertner, FC; Khawar, A; Kürpig, S; Meisenheimer, M; Roesch, F; Sinnes, JP, 2018
)
0.48
" An individual non-compartmental pharmacokinetic analysis was performed, and the mean pharmacokinetic parameters of each tissue were compared together and with reference data."( Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera
Barakat, A; Deshayes, E; Khier, S; Kotzki, PO; Santoro, L; Vivien, M, 2023
)
0.91
"This study is a proof of concept that obtaining pharmacokinetic parameters with image-based blood concentration is possible."( Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera
Barakat, A; Deshayes, E; Khier, S; Kotzki, PO; Santoro, L; Vivien, M, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"Few studies have been published on the safety and feasibility of synchronous use of peptide receptor radionuclide therapy (PRRNT), as source of internal radiation therapy, in combination with chemotherapy."( Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology.
Baum, RP; Herbst, R; Prasad, V; Salavati, A; Schneider, CP, 2012
)
0.61
"Radiotherapy using a (177)Lu-labeled GRPr antagonist alone or in combination with rapamycin was efficacious in inhibiting in vivo tumor growth and may be a promising strategy for treatment of prostate cancer."( Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
Borkowski, S; Braun, F; Dumont, RA; Maecke, H; Mansi, R; Reubi, JC; Tamma, M; Weber, WA, 2013
)
0.39
"In this first preclinical study of anti-EGFR radioimmunotherapy in breast cancer, we found that anti-EGFR radioimmunotherapy is safe and that TNBC orthotopic tumors and established metastases were eradicated in mice treated with anti-EGFR radioimmunotherapy combined with chemotherapy and PARP inhibitors."( Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
Al-Ejeh, F; Brown, MP; Chenevix-Trench, G; Khanna, KK; Lakhani, SR; Miranda, M; Shi, W; Simpson, PT; Song, S; Swarbrick, A; Vargas, AC; Welm, AL; Wiegmans, AP, 2013
)
0.39
" Application of (177)Lu-EC0800 with PMXther resulted in a two- to four-fold enhanced tumor growth delay and a prolonged survival of KB and IGROV-1 tumor-bearing mice, as compared to the combination with PMXsubther or untreated control mice."( 177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapy.
Haller, S; Leamon, CP; Müller, C; Reber, J, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" J591 is the first IgG mAb developed to target the extracellular domain of PSMA, and it has been deimmunized (humanized) to allow repeated dosing in patients."( Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabahajosula, S, 2003
)
0.32
" Repeat dosing at 45 to 60 mCi/m(2) was associated with dose-limiting myelosuppression; however, up to three doses of 30 mCi/m(2) could be safely administered."( Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabhajosula, S, 2005
)
0.65
" Initiation of recovery (at 14-21 days) showed a dose-response relationship."( Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
Mårtensson, L; Nilsson, R; Ohlsson, T; Senter, P; Sjögren, HO; Strand, SE; Tennvall, J; Wang, Z, 2005
)
0.33
" A weak but significant dose-response relationship for Gelofusine, but not for lysine, was found."( Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats.
Bernard, BF; Boerman, OC; Breeman, WA; de Blois, E; de Jong, M; Forrer, F; Gotthardt, M; Hoppin, J; Krenning, EP; Rolleman, EJ, 2008
)
0.35
" These results may be important for patients who cannot tolerate the therapeutic dosage of Herceptin currently used because of heart problems."( 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer.
Babaei, MH; Daha, FJ; Rajabi, H; Rasaneh, S, 2010
)
0.36
" Based on that result, a dosing regimen of (177)Lu-PNA-peptide, for radiologic effect, followed by the optimal mass of non-radioactive compound, for antisense effect, was designed."( Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
Balkin, ER; Jia, F; Lewis, MR; Liu, D; Miller, WH; Ruthengael, VC; Shaffer, SM, 2014
)
0.4
" Here we report the accuracy of an (111)In-labeled pretherapy test dose for personalized dosing of (177)Lu-labeled IMP288 following pretargeting with the anti-CEA × anti-hapten bsMAb, TF2, in patients with metastatic colorectal cancer (CRC)."( Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
Boerman, OC; Chang, CH; Goldenberg, DM; McBride, WJ; Oyen, WJ; Rossi, EA; Schoffelen, R; Sharkey, RM; van der Graaf, WT; Visser, EP; Woliner-van der Weg, W, 2014
)
0.4
"In 20 patients bone marrow absorbed doses (BMD) and doses to the kidneys were predicted based on blood samples and scintigrams acquired after (111)In-IMP288 injection for individualized dosing of PRIT with (177)Lu-IMP288."( Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
Boerman, OC; Chang, CH; Goldenberg, DM; McBride, WJ; Oyen, WJ; Rossi, EA; Schoffelen, R; Sharkey, RM; van der Graaf, WT; Visser, EP; Woliner-van der Weg, W, 2014
)
0.4
" PC3 tumors, and compared with the efficacy and toxicity of RIT with (177)Lu-hRS7 dosed at the maximum tolerated dose (11 MBq)."( Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
Boerman, OC; Frielink, C; Goldenberg, DM; Lütje, S; McBride, WJ; Oyen, WJ; Sharkey, RM; van Rij, CM, 2014
)
0.4
" The effects of various experimental factors including ultrasonic frequency (f), reaction solution temperature (T), catalyst dosage (Ccatalyst), initial RhB concentration (CRhB), and pH value on the sonocatalysis efficiency were investigated."( Sonocatalytic degradation of RhB over LuFeO3 particles under ultrasonic irradiation.
Li, RS; Wang, XX; Xian, T; Yang, H; Zhang, HM; Zhou, M, 2015
)
0.42
"Measurements of RIF and the absorbed dose to the blood after systemic administration of (177)Lu may be used to obtain data on the individual dose-response relationships in vivo."( DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy.
Bluemel, C; Buck, AK; Eberlein, U; Lassmann, M; Nowak, C; Scherthan, H; Werner, RA, 2015
)
0.42
"Distinct dose-response relationships were found for several of the regulated transcripts."( Potential Biomarkers for Radiation-Induced Renal Toxicity following 177Lu-Octreotate Administration in Mice.
Forssell-Aronsson, E; Helou, K; Johansson, ME; Larsson, M; Parris, TZ; Schüler, E, 2015
)
0.42
"With the experimental results and model calculations presented in this work, a dose-response relationship is demonstrated, and an analytic function describing the time course of the in vivo damage response after internal irradiation of patients with (131)I is established."( DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy.
Bluemel, C; Buck, AK; Eberlein, U; Lapa, C; Lassmann, M; Peper, M; Port, M; Scherthan, H, 2016
)
0.43
" Dosing was as follows: 97% (31/32) received two or more doses and 47% (15/32) completed six doses."( Phase I/II Trial of the Combination of
Azad, AA; Chan, L; Crumbaker, M; Danesh, A; Emmett, L; Ende, JA; Eu, P; Ho, B; Joshua, AM; Keane, J; Kongrak, K; Kwan, EM; Nguyen, A; Pathmanandavel, S; Pugh, TJ; Rofe, C; Sharma, S; Yam, AO, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
lanthanoid atom
d-block element atom
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (1,147)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (3.57)18.7374
1990's27 (2.35)18.2507
2000's204 (17.79)29.6817
2010's591 (51.53)24.3611
2020's284 (24.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.83 (24.57)
Research Supply Index7.12 (2.92)
Research Growth Index5.40 (4.65)
Search Engine Demand Index141.57 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (79.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials44 (3.69%)5.53%
Reviews77 (6.46%)6.00%
Case Studies66 (5.54%)4.05%
Observational3 (0.25%)0.25%
Other1,002 (84.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]